EMMA — Emmaus Life Sciences Share News
0.000.00%
Last trade - 00:00- $4.04m
- $30.07m
- $12.45m
Emmaus Life Sciences Q1 revenue falls driven by lower sales in U.S.
Brief: Emmaus Life Sciences Enters License And Distribution Agreement With Neoimmunetech
Emmaus Life Sciences Q3 revenue falls 38%, swings to loss
Brief: Emmaus Life Sciences CFO Yasushi Nagasaki Resigns
Brief: Emmaus Life Sciences Receives FDA Approval For Endari® Label Enhancements
Brief: Emmaus Life Sciences Q1 EPS USD -0.04
Brief: Emmaus Life Sciences Reports Improved Quarterly Financial Results
Brief: Emmaus Life Sciences Reports Q3 2022 Financial Results, Provides Business Update
Brief: Emmaus Life Sciences Reports Q2 2022 Results
Brief: Emmaus Life Sciences Reports Q2 2022 Results
Brief: Emmaus Life Sciences Posts Q1 Loss Per Share $0.03
Brief: Emmaus Life Sciences Presents Positive Transfusion Data From A Post-HOC Analysis Of Its Phase 3 Clinical Study Of Endari In Patients With Sickle Cell Disease
Brief: Emmaus Life Sciences Provides SEC Reporting Update
Brief: Emmaus Life Sciences Announces Collaboration With Kainos Medicine For Preclinical Development Of Irak4 Inhibitor As Potential Anti-Cancer Drug
Brief: Emmaus Life Sciences Announces The Sale Of Its Telcon Rf Pharmaceutical Inc. Shares
Brief: Emmaus Life Sciences Announces Engagement Of Partner International To Lead Out-Licensing Of Endari For Diverticulosis
Brief: Emmaus Life Sciences Announces Equity Purchase Agreement
Novartis, GBT sickle cell drugs too expensive, draft U.S. report says (updated)
Novartis, GBT sickle cell drugs too expensive, draft U.S. report says